- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05103124
GUM Hydral Mouthwash vs Placebo in the Management of Hyposalivation.
Efficacy of GUM Hydral Mouthwashes on Symptoms of Radiotherapy-induced Xerostomia: a Randomized, Double-blind, Crossover Study.
There is currently little robust evidence to inform the management of hyposalivation and xerostomia in this population. Although the treatment of xerostomia is very individual, a first-line medication is needed to ameliorate the dehydration in the mouth by substituting for the secretion of saliva.
The aim of this study is to describe the effect of the administration of Hydral on reducing patients' xerostomia symptoms due to radiotherapy.
The study will be conducted as a double-blind randomized clinical trial (RCT) and foresees a crossover design, so the population will be divided into two groups, receiving both the medical device and the placebo.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Head and neck squamous cell carcinoma (HNSCC) accounts for more than 750,000 new cases per year and its prognosis is still poor in terms of mortality and of morbidity and it causes approximately 350,000 deaths annually worldwide. Radiotherapy (RT) is an established treatment modality for HNSCC and other H&N tumors, either for treatment alone or as adjuvant. Unfortunately, high-dose RT has significant adverse effects on the oral and maxillofacial tissues, both hard and soft. In particular, when salivary glands are within the irradiated field, irreversible salivary glands damage occurs in 63-93% of the patients. Salivary gland damage typically manifests as reduced saliva secretion, which in turn can translate into a subjective sensation of dry mouth (xerostomia), oral discomfort, altered taste, difficulty with speaking, swallowing, chewing, and increased risk of dental disease. Overall hyposalivation and related xerostomia can cause a substantial reduction in quality-of-life (QoL). However there is currently little robust evidence to inform the management of hyposalivation and xerostomia in this population. Although the treatment of xerostomia is very individual, a first-line medication is needed to ameliorate the dehydration in the mouth by substituting for the secretion of saliva.
GUM Hydral (GUM Hydral: Sunstar Italiana SRL. Corso Italia 13 21047 Saronno, VA, Italy) is a product based on hyaluronic acid and sodium citrate. It helps in rehydrating and protecting the oral tissues, by forming a film on those tissues. It may be helpful in reducing the xerostomia symptoms.
The device is a high-density liquid and it is used as a mouthwash. In this trial, the aim is to investigate if its efficacy in reducing the xerostomia symptoms is higher than placebo.
The placebo will be made of water with xylitol in addition. Xylitol is a is a sugar alcohol used as a sugar substitute, which does not increase the risk of tooth decay. In this formulation, its only role is to give a slight sweet flavor to water.
The aim of this study is to describe the effect of the administration of Hydral on reducing patients' xerostomia symptoms due to radiotherapy.
The study will be conducted as a double-blind randomized clinical trial (RCT) and foresees a crossover design, so the population will be divided into two groups, receiving both the medical device and the placebo.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Roma, Italy, 00168
- Catholic University of the Sacred Hearth
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients willing to sign the informed consent form
- Patients older than 18 years
- Patients with diagnosis of HNC, who had received local radiotherapy at least three months before the beginning of the study, involving the salivary glands, both for curative and palliative purpose, with or without chemotherapic treatment, reporting xerostomia symptoms
- Patients with diagnosis of HNC, who had received local radiotherapy as an adjuvant to surgical resection at least three months before the beginning of the study, with or without chemotherapic treatment, reporting xerostomia symptoms-
Exclusion Criteria:
- Patients with documented contraindication to any of the components of GUM HYDRAL (there included eccipients)
- Patients with any neurological and psychiatric condition having an influence on the ability to self-apply the treatment
- Patients unwilling to complete the request diary card
- Patients unable to attend the ambulatory visits scheduled by the protocol
- Patients participating to other clinical studies
- Patients who had received antitumoral treatment during the previous three months
- Patients with concomitant Sjogren's syndrome
- Other causes of xerostomia (pharmacological treatment)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hydral
The participants will be asked to rinse their mouth five times a day with the experimental product.
After one month, the administration will be stopped and the patients will be asked to fulfill the questionnaires mentioned in the methods section (XQ, QLQ-C30, QLQ HN35)
|
The investigational product GUM Hydral will be administered for a 30-days treatment period
The placebo product will be administered for a 30-days treatment period
|
Placebo Comparator: Placebo
The participants will be asked to rinse their mouth five times a day with the placebo comparator.
After one month, the administration will be stopped and the patients will be asked to fulfill the questionnaires mentioned in the methods section (XQ, QLQ-C30, QLQ HN35)
|
The investigational product GUM Hydral will be administered for a 30-days treatment period
The placebo product will be administered for a 30-days treatment period
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of the Xerostomia Questionnaire (XQ)
Time Frame: After a one-month therapy both with Hydral and Placebo
|
The modified XQ provides a measure of the severity of radiation -induced xerostomia that affects the patients' QoL.
This questionnaire consists of 10 questions, associated with patient-reported dryness.
Moreover, a general question "how dry is your mouth?" has been added to the questionnaire.
The modified XQ is a self-administered tool and patients will be asked to rate each symptom on a 10-point NRS scale of 0-10, with higher scores indicating more severe dryness or discomfort due to dryness.
Each item score is added, and the sum is linearly transformed to produce the final summary score ranging from 0 to 100, with higher scores representing higher levels of xerostomia.
|
After a one-month therapy both with Hydral and Placebo
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of the EORTC QLQ-30 questionnaire
Time Frame: After a one-month therapy both with Hydral and Placebo
|
The QLQ-C30 provides 30 questions, globally assessing patients' quality of life.
The answers will be converted into a linear scoring scale, with values between 0 and 100, as advocated by EORTC.
|
After a one-month therapy both with Hydral and Placebo
|
Improvement of the EORTC QLQ_H&N-35 Questionnaire
Time Frame: After a one-month therapy both with Hydral and Placebo
|
The QLQ-H&N35 includes 35 questions, and addresses symptoms associated with specific tumor location, side effects associated with the oncologic treatment and additional QoL aspects modified by the disease or its treatment.
The answers will be converted into a linear scoring scale, with values between 0 and 100, as advocated by EORTC.
|
After a one-month therapy both with Hydral and Placebo
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Carlo Lajolo, Prof., CU Sacred Hearth
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SSHNC-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Xerostomia
-
Cathrine RahbekDanish Cancer Society; DLHM - Danish Society for Mouth and Throat Cancer; Danish...Active, not recruitingXerostomia Following Radiotherapy | Xerostomia Following in Neck Ore Head After CancersurgeryDenmark
-
Bedford Hospital NHS TrustUnknownXerostomia | Xerostomia Due to Radiotherapy | Xerostomia Due to Hyposecretion of Salivary Gland
-
Institute of Oncology LjubljanaUniversity Medical Centre Ljubljana; University of Ljubljana; Blood Transfusion...Not yet recruitingXerostomia Following RadiotherapySlovenia
-
Qazvin University Of Medical SciencesImam Khomeini HospitalCompletedRadiation-Induced XerostomiaIran, Islamic Republic of
-
Laboratoires CARILENEDERMSCAN-PHARMASCAN GROUP in charge of data analysisCompleted
-
Institut de Terapia Regenerativa TissularUnknownXerostomia Due to RadiotherapySpain
-
MeiraGTx, LLCActive, not recruitingRadiation-induced XerostomiaUnited States, Canada
-
Thomas KuhntVerband Deutscher DruckkammerzentrenTerminatedRadiation-induced XerostomiaGermany
-
Pierre Fabre MedicamentCompletedDrug-induced XerostomiaGermany
Clinical Trials on Hydral
-
Sunstar AmericasCompleted
-
Azienda Socio Sanitaria Territoriale degli Spedali...Sunstar SuisseCompleted